|
Market Closed -
NSE India S.E.
11:05:10 13/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 1,880.00 INR | -0.27% |
|
+1.08% | +9.32% |
| 11-04 | India proposes instant manufacturing licence suspension for drugs failing quality tests | RE |
| 11-02 | Indian shares set for positive start on talks to end Iran war, strong Reliance earnings | RE |
| Market Cap | 4,511B 47.84B 43.35B 40.1B 36.18B 68.18B 70.58B 482B 191B 2,410B 180B 176B 7,649B | P/E 2027 * |
36.7x | P/E 2028 * | 30.1x |
|---|---|---|---|---|---|
| Enterprise Value | 4,215B 44.7B 40.51B 37.47B 33.81B 63.71B 65.95B 450B 178B 2,251B 168B 164B 7,147B | EV / Sales 2027 * |
6.5x | EV / Sales 2028 * | 5.73x |
| Free-Float |
44.39% | Yield 2027 * |
0.88% | Yield 2028 * | 1.04% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| SUNPHARMA | Delayed | |
Bombay S.E.
| SUNPHARMA | Delayed |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | -0.27% | ||
| 1 week | +1.08% | ||
| Current month | +5.75% | ||
| 1 month | +6.17% | ||
| 3 months | -2.69% | ||
| 6 months | +3.02% | ||
| Current year | +9.32% |
| 1 week | 1,861 |  | 1,943.9 |
| 1 month | 1,719.1 | | 1,943.9 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,583.7 | | 2,046.9 |
| 3 years | 1,171 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 31/08/2025 | |
| Director of Finance/CFO | 58 | 30/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 31/08/2025 | |
| Director/Board Member | 71 | 20/05/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.27% | +1.08% | +8.21% | +59.62% | 48.11B | |
| +1.26% | +6.61% | +41.12% | +135.59% | 1,271B | |
| +0.79% | +3.45% | +46.35% | +93.56% | 683B | |
| +0.20% | +1.28% | +27.01% | +112.80% | 520B | |
| -0.44% | +3.69% | +39.60% | +69.51% | 389B | |
| +0.55% | +0.70% | +59.00% | +44.20% | 362B | |
| -0.12% | +0.74% | +26.78% | +58.43% | 304B | |
| +0.37% | +0.37% | +3.62% | +36.44% | 286B | |
| -0.30% | +1.14% | +38.59% | +74.61% | 253B | |
| +0.08% | +0.71% | +34.25% | +124.32% | 208B | |
| Average | +0.21% | +1.87% | +32.45% | +80.91% | 432B | |
| Weighted average by Cap. | +0.53% | +2.68% | +37.28% | +95.69% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 648B 6.87B 6.23B 5.76B 5.2B 9.8B 10.14B 69.2B 27.44B 346B 25.79B 25.25B 1,099B | 723B 7.67B 6.95B 6.43B 5.8B 10.93B 11.32B 77.24B 30.63B 386B 28.79B 28.18B 1,227B |
| Net income | 122B 1.29B 1.17B 1.08B 976M 1.84B 1.9B 13B 5.15B 65.03B 4.85B 4.74B 206B | 150B 1.59B 1.44B 1.33B 1.2B 2.27B 2.35B 16.03B 6.36B 80.21B 5.98B 5.85B 255B |
| Net Debt | -296B -3.14B -2.84B -2.63B -2.37B -4.47B -4.63B -31.61B -12.53B -158B -11.78B -11.53B -502B | -366B -3.89B -3.52B -3.26B -2.94B -5.54B -5.73B -39.13B -15.52B -196B -14.59B -14.28B -621B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/11/26 | ₹1,880.00 | -0.27% | 2,037,762 |
| 12/11/26 | ₹1,885.00 | -0.91% | 2,464,003 |
| 11/11/26 | ₹1,902.30 | -0.12% | 2,262,492 |
| 09/11/26 | ₹1,904.50 | -0.55% | 3,127,099 |
| 08/11/26 | ₹1,915.00 | +2.96% | 971,660 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
